Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA 1: Delgocitinib cream for chronic hand eczema
NCT04871711Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic hand eczema (CHE) comparing Delgocitinib with Vehicle (2 arms). Primary endpoint: Investigator's Global Assessment for Chronic Hand Eczema Treatment Success at 16 weeks. Started May 2021; status: completed.
02
Drugs
delgocitinib
03
Conditions
chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT04871711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871711.